Thrombolytic Science Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

Thrombolytic Science, a privately held biotechnology company based in Cambridge, Massachusetts, is focused on vascular medicine and the development of a next-generation clot-dissolving therapy. Its approach centers on a rationally designed mutant form of pro-urokinase, aiming to deliver a novel mechanism of action for treating stroke and other thrombotic diseases, with the potential to address unmet needs in thrombolysis. The company collaborates with external partners, such as Clinical Accelerator Ltd, to conduct phase II clinical study work, exemplified by a planned mechanistic trial in patients with ST-elevation myocardial infarction under a multi-centre, randomized framework. With a small team, TSI operates within the biotechnology research sector, seeking to advance thrombosis treatment through innovative vascular medicine research. The information indicates the company’s activities are anchored in its research-and-development mission and early-phase clinical investigation, located in the Cambridge area of Massachusetts.» } uniqueness:1 } } {

Get verified Thrombolytic Science emails free

Company overview Employee directory